Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cancer Oesophagus Gefitinib (COG)
2007-005391-13Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in esophageal cancer, esophageal adenocarcinoma (EAC) and Esophageal Squamous Cell Carcinoma (ESCC) comparing Gefitinib (Iressa) with Placebo (2 arms). Primary endpoints: Overall survival and Toxicity of gefitinib monotherapy. Started Oct 2008; status: completed.
02
Drugs
03
Conditions
esophageal canceresophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2007-005391-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005391-13.